Sanofi (SNY)
(Delayed Data from NSDQ)
$55.47 USD
-0.07 (-0.13%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $55.48 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$55.47 USD
-0.07 (-0.13%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $55.48 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
Merck's Partner Gets FDA Nod for Herceptin Biosimilar
by Zacks Equity Research
Merck's (MRK) partner, Samsung Bioepis Co. gets FDA approval for Ontruzant, a Herceptin Biosimilar.
Top Ranked Income Stocks to Buy for January 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, January 21st:
Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY
by Zacks Equity Research
Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.
Top Ranked Income Stocks to Buy for January 18th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, January 18th
Regeneron (REGN) Sails Steady on Label Expansion of Drugs
by Zacks Equity Research
Regeneron's (REGN) performance has been steady in the past six months even as the overall industry declines.
Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results
by Zacks Equity Research
Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.
Regeneron, Sanofi Restructure Immuno-Oncology Collaboration
by Zacks Equity Research
Regeneron (REGN) amends its existing agreement with Sanofi and selects two clinical-stage bispecific antibodies for the ongoing collaboration.
Emergent (EBS) Files Application for Emergency Use of NuThrax
by Zacks Equity Research
Emergent (EBS) submits an application to the FDA for the emergency use of its anthrax vaccine candidate, NuThrax.
Sanofi Wins FDA Nod for Pediatric Hexavalent Combo Vaccine
by Zacks Equity Research
Sanofi (SNY) gains an FDA approval for its pediatric hexavalent combination vaccine, Vaxelis.
The Zacks Analyst Blog Highlights: Apple, Microsoft, Mastercard, Sanofi and Dominion Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Microsoft, Mastercard, Sanofi and Dominion Energy
Top Analyst Reports: Apple, Microsoft, Mastercard & More
by Kalyan Nandy
Today's Research Daily features updated research reports on 16 major stocks including Apple Inc. (AAPL), Microsoft Corporation (MSFT) and Mastercard Inc. (MA).
Mylan (MYL) Gets Favorable Ruling Against Sanofi's Lantus
by Zacks Equity Research
Mylan (MYL) gets a favorable ruling from the U.S. PTAB against Sanofi for Lantus.
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
by Kinjel Shah
Here are five stocks that are attractive and most likely to be takeout targets in 2019.
4 Big Pharma Stocks to Add to Your Portfolio in December
by Kinjel Shah
The large-cap pharma industry has been on a strong footing lately. Here are four stocks from the space that investors may consider betting on.
Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs
by Zacks Equity Research
FDA grants approval to Pfizer's (PFE) new cancer drug and label expansion of AbbVie/Roche's Venclexta. CHMP gives nod to several drugs
The Zacks Analyst Blog Highlights: Sanofi, Novo Nordisk, NVIDIA, Fifth Third Bancorp and Continental Resources
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sanofi, Novo Nordisk, NVIDIA, Fifth Third Bancorp and Continental Resources
Glaxo Seeks Label Expansion of Nucala in Pediatric Patients
by Zacks Equity Research
Glaxo (GSK) submits sBLA to the FDA seeking label expansion of its asthma drug, Nucala, in pediatric patients in the United States.
Top Stock Reports for Sanofi, Novo Nordisk & NVIDIA
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Sanofi (SNY), Novo Nordisk (NVO) and NVIDIA (NVDA).
Alphabet Halts Glucose Lens Work to Focus on Other Projects
by Zacks Equity Research
Alphabet's (GOOGL) healthcare unit Verily halts the glucose-measuring contact lens project in order to allocate its resources to other valuable projects.
Regeneron (REGN) Rides on Eylea and Dupixent's Performance
by Zacks Equity Research
Solid performance of approved drugs like Eylea and Dupixent along with an encouraging pipeline progress improve Regeneron's (REGN) market position.
Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges
by Zacks Equity Research
With the earnings season coming to an end, data presentations on key drugs and candidates hog the limelight this week.
Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Merrimack (MACK) discourages with Q3 loss, falling shy of estimates as well as deteriorates from the year-ago quarter's figure. Also, the company fails to reap any revenues in the period.
Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug
by Zacks Equity Research
Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.
Alnylam's (ALNY) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Alnylam (ALNY) incurs wider-than-expected loss year over year in the third quarter of 2018 and reiterates guidance for the year.
Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron announce priority review to label expansion application of Dupixent seeking approval in adolescent patients with moderate-to-severe atopic dermatitis.